淋巴瘤的免疫治疗进展  

Advances of immunotherapy in lymphoma

作　　者：郏博[1] 石远凯[1] 

机构地区：[1]北京协和医学院中国医学科学院肿瘤医院内科抗肿瘤分子靶向药物临床研究北京市重点实验室,100021

出　　处：《白血病．淋巴瘤》2015年第10期577-579,共3页Journal of Leukemia & Lymphoma

基　　金：国家科技支撑计划（2014BA109812）

摘　　要：近年来淋巴瘤的发病率逐渐上升,已经成为最常见的恶性肿瘤之一.新的化疗方案、单克隆抗体、小分子靶向药物等治疗方式已经显著改善了淋巴瘤患者的生存.但是,淋巴瘤患者出现复发或耐药的比例仍然很高,因此针对这些患者寻找新的治疗方式至关重要.细胞免疫治疗可以通过引发特异有效的抗肿瘤免疫反应杀灭肿瘤.继承性细胞免疫疗法、免疫调节药物、免疫检查点治疗等免疫治疗方式在复发/难治淋巴瘤患者的治疗中取得了显著的疗效,逐渐开启了淋巴瘤治疗的新时代.Over the past years, the incidence of lymphoma has been increasing, which has become one of the most common cancers around the world.The survival of lymphoma patients has been significantly improved due to advances of therapeutic methods such as new chemotherapy regimens, monoclonal antibodies and small molecular targeted drugs.However, the number of patients with relapsed/refractory lymphoma still account for a large proportion.It is of great significance to find new ways to treat these patients.Cellular immunotherapy could kill tumor cells by causing specific and effective antitumor immune response.Remarkable advances have been made in immunotherapy, such as adoptive immunotherapy, immune checkpoint inhibitors and immunomodulation therapy, for relapsed/refractory lymphoma patients, which will gradually open a new era in the treatment of lymphoma.

关 键 词：淋巴瘤 免疫治疗 免疫调节 免疫检查点 

分 类 号：R733.1[医药卫生—肿瘤]